148 related articles for article (PubMed ID: 37526606)
1. Abnormal bone marrow findings in patients following treatment with chimeric antigen receptor-T cell therapy.
Yeung CCS; Woolston DW; Wu V; Voutsinas JM; Basom R; Davis C; Hirayama AV; Naresh KN
Eur J Haematol; 2024 Jan; 112(1):111-121. PubMed ID: 37526606
[TBL] [Abstract][Full Text] [Related]
2. Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party.
Penack O; Peczynski C; Koenecke C; Polge E; Kuhnl A; Fegueux N; Daskalakis M; Kröger N; Dreger P; Besley C; Schanz U; Bloor A; Ganser A; Forcade E; Corral LL; Passweg JR; Novak U; Moiseev I; Schoemans H; Basak GW; Chabannon C; Sureda A; Averbuch D; Glass B; de la Camara R; Peric Z
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37072350
[TBL] [Abstract][Full Text] [Related]
3. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
Front Immunol; 2021; 12():755549. PubMed ID: 34777367
[TBL] [Abstract][Full Text] [Related]
4. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.
Pan J; Tang K; Luo Y; Seery S; Tan Y; Deng B; Liu F; Xu X; Ling Z; Song W; Xu J; Duan J; Wang Z; Li C; Wang K; Zhang Y; Yu X; Zheng Q; Zhao L; Zhang J; Chang AH; Feng X
Lancet Oncol; 2023 Nov; 24(11):1229-1241. PubMed ID: 37863088
[TBL] [Abstract][Full Text] [Related]
5. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.
Leahy AB; Newman H; Li Y; Liu H; Myers R; DiNofia A; Dolan JG; Callahan C; Baniewicz D; Devine K; Wray L; Aplenc R; June CH; Grupp SA; Rheingold SR; Maude SL
Lancet Haematol; 2021 Oct; 8(10):e711-e722. PubMed ID: 34560014
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow microenvironment disruption and sustained inflammation with prolonged haematologic toxicity after CAR T-cell therapy.
Kitamura W; Asada N; Naoi Y; Abe M; Fujiwara H; Ennishi D; Nishimori H; Fujii K; Fujii N; Matsuoka KI; Yoshino T; Maeda Y
Br J Haematol; 2023 Jul; 202(2):294-307. PubMed ID: 36890790
[TBL] [Abstract][Full Text] [Related]
7. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
8. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL.
Rejeski K; Perez A; Iacoboni G; Penack O; Bücklein V; Jentzsch L; Mougiakakos D; Johnson G; Arciola B; Carpio C; Blumenberg V; Hoster E; Bullinger L; Locke FL; von Bergwelt-Baildon M; Mackensen A; Bethge W; Barba P; Jain MD; Subklewe M
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580927
[TBL] [Abstract][Full Text] [Related]
9. Humanized CD19-directed CAR-T Cell Therapy in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia With CNSL or Neurological Comorbidity.
Zhang N; Shao J; Li H; Zhu J; Xia M; Chen K; Jiang H
J Immunother; 2022 Nov-Dec 01; 45(9):396-406. PubMed ID: 36018262
[TBL] [Abstract][Full Text] [Related]
10. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.
Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J
Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of peripheral eosinophil counts in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy.
Dang X; Ye S; Zhou L; Lu Y; Li P; Liang A; Qian W
Cytotherapy; 2023 Jun; 25(6):573-577. PubMed ID: 36456447
[TBL] [Abstract][Full Text] [Related]
13. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells.
Strati P; Li X; Deng Q; Marques-Piubelli ML; Henderson J; Watson G; Deaton L; Cain T; Yang H; Ravanmehr V; Fayad LE; Iyer SP; Nastoupil LJ; Hagemeister FB; Parra ER; Saini N; Takahashi K; Fowler NH; Westin JR; Steiner RE; Nair R; Flowers CR; Wang L; Ahmed S; Al-Atrash G; Vega F; Neelapu SS; Green MR
Cell Rep Med; 2023 Aug; 4(8):101158. PubMed ID: 37586321
[TBL] [Abstract][Full Text] [Related]
14. Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors.
Xia Y; Zhang J; Li J; Zhang L; Li J; Fan L; Chen L
Ann Med; 2022 Dec; 54(1):2951-2965. PubMed ID: 36382675
[TBL] [Abstract][Full Text] [Related]
15. Impact of Rituximab and Corticosteroids on Late Cytopenias Post-Chimeric Antigen Receptor T Cell Therapy.
Iqbal M; Bansal R; Yassine F; Gandhi S; Rosenthal A; Moustafa MA; Li Z; Craver EC; Mohty R; Murthy H; Ayala E; Tun H; Munoz J; Castro J; Lin Y; Kharfan-Dabaja MA
Transplant Cell Ther; 2022 Oct; 28(10):668.e1-668.e6. PubMed ID: 35842124
[TBL] [Abstract][Full Text] [Related]
16. Factors Impacting Overall and Event-Free Survival following Post-Chimeric Antigen Receptor T Cell Consolidative Hematopoietic Stem Cell Transplantation.
Molina JC; Steinberg SM; Yates B; Lee DW; Little L; Mackall CL; Shalabi H; Shah NN
Transplant Cell Ther; 2022 Jan; 28(1):31.e1-31.e9. PubMed ID: 34687939
[TBL] [Abstract][Full Text] [Related]
17. Adenovirus-induced hemorrhagic cystitis after CD19-targeted chimeric antigen receptor T-cell therapy in a patient with large B-cell lymphoma.
Medina I; Carpio C; Ruiz-Camps I; Albasanz-Puig A; Lopez-Godino O; Esperalba J; Beas F; Sanchez-Salinas M; Iacoboni G; Barba P
Immunotherapy; 2023 Nov; 15(16):1369-1374. PubMed ID: 37718888
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
[TBL] [Abstract][Full Text] [Related]
19. Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma.
Zhou J; Zhang Y; Shan M; Zong X; Geng H; Li J; Chen G; Yu L; Xu Y; Li C; Wu D
Front Immunol; 2022; 13():997589. PubMed ID: 36131934
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of Anti-CD19 CAR-T Treatment of Pediatric B-ALL with Bone Marrow and Extramedullary Relapse.
Wan X; Yang X; Yang F; Wang T; Ding L; Song L; Miao Y; Wang X; Ma Y; Luo C; Tang J; Gu L; Chen J; Tang Y; Lu J; Li B
Cancer Res Treat; 2022 Jul; 54(3):917-925. PubMed ID: 34583462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
